e-Drug3D

1624

MONOMETHYL FUMARATE

INN
MONOMETHYL FUMARATE

cas 2756-87-8

CLASS

IMMUNOSUPPRESSANTS
TREATMENT OF TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
ACTIVATES THE NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) PATHWAY
NICOTINIC ACID RECEPTOR AGONIST

ROUTE (list)

ORAL

ATC code

L04AX07

PK parameters

Tmax 2.25 HOUR
VD 63 LITER
Cl 43.6 LITER / HOUR (EQN)
PPB 36 PERCENT
t1/2 1 HOUR

Target

TARGET NICOTINIC ACID RECEPTOR (NIACR)

PDB
8JHN (STRUCTURE OF MMF-GPR109A-G PROTEIN COMPLEX)

Ligand code = UR9 (link to the list of PDB complexes)

Download experimental 3D coordinates of UR9 with added hydrogens

DrugCentral

Kelch-like ECH-associated protein 1 UNIPROT Q14145 KEAP1

Download SDF file

2-Butenedioic acid (2E)-, 1-methyl ester

Formula:
C5H6O4

Calculated chemical properties:

MW 129.09
NB_atoms 9
XLogP -1.53
PSA 62.718
NB_HD 0
NB_HA 4
fsp3 0.20
Lipinski(0=no;1=yes) 1

FDA
NDA 210296 (label) INN (MONOMETHYL FUMARATE) BAFIERTAM (BANNER LIFE SCIENCES) APPROVAL= AP YEAR= 2020